Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOPAZ-1: Durvalumab + gemcitabine + cisplatin vs placebo + gemcitabine + cisplatin in first-line advanced biliary tract cancer
jRCT2080224730Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in biliary cancer, cholangiocarcinoma (CCA) and gallbladder cancer comparing Durvalumab + gemcitabine + cisplatin with Placebo + gemcitabine + cisplatin (2 arms). Primary endpoint: Overall survival. Started Jun 2019; status: completed.
02
Drugs
durvalumab
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on jRCT2080224730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224730.